Milestone Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Milestone Pharmaceuticals (MIST).

Price Target Range — 12 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$7Upside to Avg. PT+912.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 3, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$8
Aug 20, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Initiate	Overweight	$3
May 14, 2026	Wells Fargo	Mohit Bansal	PT Cut	Overweight	$8→$7
Jan 6, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$8
Dec 16, 2025	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$4→$8
Dec 15, 2025	TD Cowen	Ritu Baral	Upgrade	Hold→Buy	$8
Dec 15, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$5→$8
Sep 11, 2025	Wells Fargo	Mohit Bansal	Initiate	Overweight	$4
Jun 5, 2025	HC Wainwright & Co.	Brandon Folkes	Assumes	Buy	$5
Apr 1, 2025	HC Wainwright & Co.	Patrick Trucchio	PT Cut	Buy	$25→$10
Mar 28, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$25
Mar 17, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$25
Feb 28, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$25
Jan 27, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$25
Oct 14, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$25
Aug 22, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$25
Aug 22, 2024	Rodman & Renshaw	Brandon Folkes	Initiate	Buy	$9
Jul 1, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$25
May 30, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$25
May 16, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$25

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $8 price target.

Benzinga Newsdesk

This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page for full details and stock recommendations.

Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $3

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and announces Price Target of $3.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7

Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $8 to $7.

Benzinga Newsdesk

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16 cents per share on $1.20M revenue.

Avi Kapoor

PRO
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $8 price target.

Benzinga Newsdesk

Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target

This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $3

PRO
Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

PRO
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target

People Also Watch

People Also Watch

Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target

This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PROCantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $3

PROWells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

PROHC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target

PRO
Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $3

PRO
Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7

PRO
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target